Table 2.
Change from baseline in SpO2/FiO2 ratio (efficacy population)
| Parameter | Visit | Placebo (N = 20) |
Eclitasertib 600 mg (N = 47) |
|---|---|---|---|
| Change from baseline in SpO2/FiO2 ratio | Day 02 | 49.91 (− 24.29 to 124.12) | 72.02 (− 1.53 to 145.56) |
| Day 03 | 82.04 (5.68 to 158.39) | 97.90 (23.35 to 172.45) | |
| Day 04 | 84.91 (5.95 to 163.87) | 104.61 (28.83 to 180.39) | |
| Day 05 | 102.55 (23.28 to 181.82) | 121.79 (45.87 to 197.72) | |
| Day 06 | 105.95 (26.73 to 185.18) | 134.66 (58.76 to 210.57) | |
| Day 07 | 116.97 (36.66 to 197.29) | 142.21 (65.78 to 218.63) | |
| Day 15 | 150.78 (71.65 to 229.90) | 174.65 (98.79 to 250.51) | |
| Eclitasertib vs. placebo on Day 07 | 25.24 (− 21.54 to 72.01) | ||
N: Number of patients; SpO2/FiO2: Peripheral oxygen saturation/Fraction of inspired oxygen
Values are point estimates of the mean absolute change from baseline in SpO2/FiO2 ratio (90% CI). A positive value in the change indicates a larger ratio at the day of measurement than at baseline